Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Rilzabrutinib for the treatment of immune thrombocytopenia (ITP) as of September 2025

MARA Rating Company December 16, 2025

Sotatercept for treatment of heart failure with preserved ejection fraction complicated by combined pulmonary hypertension as of November 2025

MARA Rating Company December 16, 2025

Zolbetuximab for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive as of March 2025

MARA Rating Company December 16, 2025

Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy as of August 2025

MARA Rating Company December 16, 2025

Brensocatib for treating non-cystic fibrosis bronchiectasis as of August 2025

MARA Rating Company December 16, 2025

Cenobamate for treating focal onset seizures in epilepsy as of July 2025

MARA Rating Company December 16, 2025

Datopotamab deruxtecan for the treatment of HR-positive, HER2-negative metastatic breast cancer as of August 2025

MARA Rating Company December 16, 2025

Donanemab for slowing cognitive decline in early Alzheimer’s disease as of August 2025

MARA Rating Company December 16, 2025

Elexacaftor for treating cystic fibrosis as of August 2025

MARA Rating Company December 16, 2025

Fruquintinib for previously treated metastatic colorectal cancer as of July 2025

MARA Rating Company December 16, 2025